Patent · US Active

Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug

US8394791B2 · kind B2 · utility

0Cited by

11References

7Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Ulrike Werthmann · Biberach an der Riß, DE
Marco Santagostino · Magenta, IT
Adil Duran · Biberach an der Riß, DE

Key dates

Filing date	Feb 17, 2009
Grant date	Mar 12, 2013
Priority date	—
Expiry date	Aug 31, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

This invention concerns a crystalline, enantiopure hydrochloride salt of N-(5-{2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide, preferably of N-(5-{(R)-2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide and its action as a long acting beta-agonist, alone or in combination with one or multiple other active ingredients for the treatment of respiratory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.